成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Anti-AKT1 antibody - 蛋白激酶B抗體,AKT1
  • Anti-AKT1 antibody - 蛋白激酶B抗體,AKT1
  • Anti-AKT1 antibody - 蛋白激酶B抗體,AKT1

Anti-AKT1 antibody - 蛋白激酶B抗體

價(jià)格 1098 1880 2900
包裝 50ul 100ul 200ul
最小起訂量 50ul
發(fā)貨地 上海
文件下載 檢測(cè)報(bào)告COA
更新日期 2024-11-07
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:Anti-AKT1 antibody - 蛋白激酶B抗體英文名稱:AKT1
品牌: 滬震生物產(chǎn)地: 中國(guó)/上海
保存條件: -20°C純度規(guī)格: > 99%
產(chǎn)品類別: 抗體 一抗
抗體名: AKT 1; AKT; AKT-1; AKT1_HUMAN; C AKT; cAKT; MGC9965; MGC99656; Oncogene AKT1; PKB; PKB alpha; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene c-Akt; RAC Alpha; RAC alpha serine/threonine protein kinase; RAC; RAC PK Alpha; Rac protein kinase alpha; RAC Serine/Threonine Protein Kinase; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; v akt murine thymoma viral oncogene homolog 1; vAKT Murine Thymoma Viral Oncogene Homolog 1. 靶點(diǎn): 詳見說明書
宿主: Mouse適應(yīng)物種: 詳見說明書
克隆性: 詳見說明書濃度: 1mg/ml
應(yīng)用范圍: WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100 IF=1:100-500 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.標(biāo)識(shí)物: 詳見說明書
形態(tài): 液體亞型: IgG1
免疫原: 詳見說明書貨號(hào): HZM-M0115
用途范圍: 科研使用規(guī)格: 50ul/100ul/200ul
是否進(jìn)口: 是否單克隆: 詳見說明書
保質(zhì)期: 12個(gè)月抗原來源: 詳見說明書
標(biāo)記物: 詳見說明書產(chǎn)品用途: WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100 IF=1:100-500 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
2024-11-07 Anti-AKT1 antibody - 蛋白激酶B抗體 AKT1 50ul/1098RMB;100ul/1880RMB;200ul/2900RMB 1098 滬震生物 中國(guó)/上海 -20°C > 99% 抗體 一抗

Host:Mouse

Target Protein:AKT1

IR:Immunogen Range:401-479/479

Clonality:Polyclonal

Isotype:IgG

Entrez Gene:207

Swiss Prot:P31749

Source:KLH conjugated synthetic peptide derived from human AKT-1:401-479/479 

Purification:affinity purified by Protein A

Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Background:This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]

Size:50ul

Concentration:1mg/ml

Applications:WB(1:500-2000)
ELISA(1:5000-10000)
IHC-P(1:100-500)
IHC-F(1:100-500)
ICC(1:100)
IF(1:100-500)

Cross Reactive Species:Human
Mouse
Rat
Chicken
Dog
Pig
Cow
Rabbit
Sheep
.

搜狗截圖23年04月20日1751_22.png




本產(chǎn)品僅供科研使用。不能用于人和動(dòng)物治療等其它臨床診斷使用!












































































































關(guān)鍵字: AKT1;AKT 1;AKT-1;C AKT;CAKT;

公司簡(jiǎn)介

上海滬震實(shí)業(yè)有限公司是一家集研發(fā)、生產(chǎn)和銷售于一體的生命科學(xué)實(shí)驗(yàn)室產(chǎn)品生物科技企業(yè)。主營(yíng)產(chǎn)品:試劑盒,ELISA試劑盒,抗體,重組蛋白,血清,胎牛血清,細(xì)胞,原代細(xì)胞 細(xì)胞培養(yǎng)試劑,常用生化試劑。
成立日期 2014-05-08 (11年) 注冊(cè)資本 100萬(wàn)元整
員工人數(shù) 10-50人 年?duì)I業(yè)額 ¥ 100萬(wàn)以內(nèi)
主營(yíng)行業(yè) 生化試劑,細(xì)胞培養(yǎng),蛋白組學(xué),分子生物學(xué),細(xì)胞生物學(xué) 經(jīng)營(yíng)模式 工廠,試劑,定制,服務(wù)
  • 上海滬震實(shí)業(yè)有限公司
VIP 3年
  • 公司成立:11年
  • 注冊(cè)資本:100萬(wàn)元整
  • 企業(yè)類型:有限責(zé)任公司(國(guó)內(nèi)合資)
  • 主營(yíng)產(chǎn)品:ELISA試劑盒,抗體,細(xì)胞系,原代細(xì)胞,細(xì)胞培養(yǎng)試劑,重組蛋白
  • 公司地址:松江區(qū)
詢盤

Anti-AKT1 antibody - 蛋白激酶B抗體相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
詢價(jià)
上海炎熙生物科技有限公司
2024-11-05
詢價(jià)
VIP4年
上海冠導(dǎo)生物工程有限公司
2024-11-07
詢價(jià)
南京安研生物科技有限公司
2024-05-27
詢價(jià)
VIP1年
北京百普賽斯生物科技股份有限公司
2024-10-29
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的